Related Experiment Videos
Characterization and extracorporeal application of a new phosphate-binding agent
K Spengler1, H Follmann, K S Boos
1Universität Kassel, Fachbereich Biologie-Chemie, Biochemie, Germany.
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies
|October 1, 1994
Summary
A novel iron(III)oxide-hydroxide-modified dextran effectively binds phosphate without severe side effects. This new adsorbent shows promise for treating hyperphosphatemia during hemodialysis.
Area of Science:
- Biomaterials science
- Nephrology
- Analytical chemistry
Background:
- Hyperphosphatemia is a common complication in patients with chronic kidney disease, particularly those undergoing hemodialysis.
- Conventional phosphate-binding agents can cause gastrointestinal side effects and may have limited efficacy.
- There is a need for novel, safe, and effective phosphate binders.
Purpose of the Study:
- To develop and characterize a new phosphate-binding agent based on polynuclear iron(III)oxide-hydroxide-modified dextran.
- To evaluate the phosphate-binding capacity and biocompatibility of the novel agent.
- To investigate the therapeutic potential of the agent in an extracorporeal blood perfusion system for hyperphosphatemia treatment.
Main Methods:
- Modification of crosslinked dextran with polynuclear iron(III)oxide-hydroxide.
- Characterization of iron content and oxidation state using ESCA and Mössbauer spectroscopy.
- Determination of phosphate binding capacity in aqueous solutions, serum, and whole blood.
- Assessment of biocompatibility through evaluation of whole blood count, hemolysis, protein concentration, and enzyme activities.
- Investigation of factors influencing phosphate uptake (concentration, pH, temperature).
- In vitro testing in an extracorporeal blood perfusion system.
Main Results:
- The developed agent, iron(III)oxide-hydroxide-modified dextran, has a particle size of 150-300 microns and approximately 18% iron content.
- The material demonstrated significant phosphate binding capacity across various media.
- Biocompatibility tests showed no severe adverse effects on blood parameters, hemolysis, protein concentration, or enzyme activities.
- Phosphate uptake was influenced by phosphate concentration, pH, and temperature.
- Initial experiments in an extracorporeal system showed therapeutic potential for hyperphosphatemia.
Conclusions:
- The novel iron(III)oxide-hydroxide-modified dextran is a promising biocompatible phosphate binder.
- This material offers a potential alternative to existing phosphate-binding agents for managing hyperphosphatemia.
- Further in vivo studies are warranted to confirm its therapeutic efficacy and safety in hemodialysis patients.